AI Engines For more Details: Perplexity Kagi Labs You
Anticoccidial Effect: Sulfaquinoxaline sodium salt is an antimicrobial agent that belongs to the sulfa drug class. It works by interfering with the metabolism of the coccidia parasites, thereby inhibiting their growth and reproduction within the host animal's intestinal tract.
Coccidiosis Treatment: Sulfaquinoxaline sodium salt is effective in the treatment of coccidiosis in poultry (such as chickens, turkeys, and ducks), as well as in other livestock species (such as cattle, sheep, goats, and pigs). It helps to reduce the severity of clinical signs associated with coccidiosis, such as diarrhea, weight loss, decreased feed intake, and poor growth performance.
Coccidiosis Prevention: In addition to its therapeutic use, sulfaquinoxaline sodium salt is also employed as a preventive measure to control coccidiosis outbreaks in livestock populations. It can be administered prophylactically to susceptible animals during periods of increased risk, such as during transportation, introduction to new environments, or changes in management practices.
Broad Spectrum Activity: Sulfaquinoxaline sodium salt exhibits broad-spectrum activity against various species of Eimeria parasites that commonly infect poultry and livestock, including Eimeria tenella, Eimeria acervulina, Eimeria maxima, and Eimeria necatrix, among others.
Dosage and Administration: The dosage and administration of sulfaquinoxaline sodium salt may vary depending on the species of animal being treated, the severity of the coccidiosis infection, and other factors such as body weight and age. It is typically administered orally or mixed with feed or drinking water according to the manufacturer's instructions or veterinary recommendations.
Withdrawal Period: In food-producing animals, it is important to observe any required withdrawal periods specified on the product label or by regulatory authorities to ensure that residues of sulfaquinoxaline sodium salt are not present in edible tissues or products (such as meat, milk, or eggs) beyond safe levels.
Adverse Effects: While sulfaquinoxaline sodium salt is generally well tolerated by animals when used appropriately, adverse effects such as allergic reactions, gastrointestinal disturbances (such as diarrhea or vomiting), and rare instances of sulfa drug toxicity (including hypersensitivity reactions or hematological abnormalities) may occur in some individuals.
Contraindications: Sulfaquinoxaline sodium salt should be used with caution in animals with known hypersensitivity to sulfa drugs or a history of adverse reactions. It is not recommended for use in certain animal species or under specific conditions as determined by the prescribing veterinarian.
Veterinary Supervision: Sulfaquinoxaline sodium salt should be used under the guidance and supervision of a licensed veterinarian who can provide appropriate diagnosis, treatment recommendations, and monitoring of the animal's response to therapy.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
Acne | 0.3 | 0.3 | 0 |
ADHD | 1.4 | 0.3 | 3.67 |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.5 | 0.2 |
Allergies | 1.1 | 1.4 | -0.27 |
Allergy to milk products | 0.7 | 0.6 | 0.17 |
Alzheimer's disease | 2.3 | 2.3 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.4 | 2.25 |
Ankylosing spondylitis | 0.6 | 0.6 | 0 |
Anorexia Nervosa | 0.6 | 1.4 | -1.33 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 1.3 | 0.9 | 0.44 |
Atherosclerosis | 1.4 | 0.5 | 1.8 |
Atrial fibrillation | 1.4 | 0.6 | 1.33 |
Autism | 1.9 | 2 | -0.05 |
Autoimmune Disease | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.3 | -0.3 | |
Bipolar Disorder | 0.6 | 0.3 | 1 |
Brain Trauma | 0.3 | 0.9 | -2 |
Breast Cancer | 0.3 | 0.3 | 0 |
Cancer (General) | 0.3 | 1 | -2.33 |
Carcinoma | 1.2 | 1.2 | 0 |
Celiac Disease | 1.1 | 1.2 | -0.09 |
Cerebral Palsy | 0.6 | 0.6 | 0 |
Chronic Fatigue Syndrome | 1.5 | 1.3 | 0.15 |
Chronic Kidney Disease | 0.9 | 0.1 | 8 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Urticaria (Hives) | 0.6 | -0.6 | |
Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
Cognitive Function | 0.9 | 0.6 | 0.5 |
Colorectal Cancer | 2.8 | 0.6 | 3.67 |
Constipation | 0.6 | 0.6 | |
Coronary artery disease | 0.3 | 1.1 | -2.67 |
COVID-19 | 2.4 | 3.4 | -0.42 |
Crohn's Disease | 2.1 | 1.9 | 0.11 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.7 | -0.7 | |
deep vein thrombosis | 0.9 | 0.6 | 0.5 |
Depression | 3.6 | 1.9 | 0.89 |
Dermatomyositis | 0.3 | -0.3 | |
Eczema | 0.9 | -0.9 | |
Endometriosis | 0.6 | 0.6 | 0 |
Epilepsy | 1.1 | 0.8 | 0.38 |
erectile dysfunction | 0.3 | 0.3 | 0 |
Fibromyalgia | 0.3 | 0.9 | -2 |
Functional constipation / chronic idiopathic constipation | 1.7 | 2 | -0.18 |
gallstone disease (gsd) | 0.8 | 0.4 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.5 | |
Generalized anxiety disorder | 0.4 | 0.6 | -0.5 |
Gout | 1.3 | 0.4 | 2.25 |
Graves' disease | 0.9 | 0.9 | 0 |
Gulf War Syndrome | 1.6 | -1.6 | |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 1.5 | 0.7 | 1.14 |
Heart Failure | 0.6 | 0.7 | -0.17 |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
High Histamine/low DAO | 0.6 | -0.6 | |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
hyperglycemia | 0.6 | 0.8 | -0.33 |
Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | |
hypertension (High Blood Pressure | 1.2 | 2.4 | -1 |
Hypothyroidism | 0.1 | 0.3 | -2 |
Hypoxia | 0.6 | 0.3 | 1 |
IgA nephropathy (IgAN) | 0.6 | 1.3 | -1.17 |
Inflammatory Bowel Disease | 1.8 | 2.2 | -0.22 |
Insomnia | 0.3 | 0.8 | -1.67 |
Intelligence | 0.7 | 0.7 | |
Intracranial aneurysms | 0.6 | 0.3 | 1 |
Irritable Bowel Syndrome | 2.8 | 1.5 | 0.87 |
ischemic stroke | 0.9 | 0.3 | 2 |
Liver Cirrhosis | 1.7 | 1.7 | 0 |
Long COVID | 2.1 | 2.1 | 0 |
Lung Cancer | 0.6 | 0.4 | 0.5 |
Mast Cell Issues / mastitis | 0.6 | -0.6 | |
ME/CFS with IBS | 0.6 | -0.6 | |
ME/CFS without IBS | 0.6 | -0.6 | |
Menopause | 0.1 | 0.1 | 0 |
Metabolic Syndrome | 2.3 | 2.3 | 0 |
Mood Disorders | 3.8 | 1.3 | 1.92 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
Multiple Sclerosis | 0.8 | 1.4 | -0.75 |
Multiple system atrophy (MSA) | 0.2 | 0.6 | -2 |
neuropathic pain | 0.8 | -0.8 | |
Neuropathy (all types) | 0.1 | 0.4 | -3 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 1.5 | -0.67 |
NonCeliac Gluten Sensitivity | 0.7 | 0.6 | 0.17 |
Obesity | 3.1 | 2.8 | 0.11 |
obsessive-compulsive disorder | 1.4 | 1.1 | 0.27 |
Osteoarthritis | 0.7 | 0.9 | -0.29 |
Osteoporosis | 0.6 | 0.4 | 0.5 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 2.4 | 1.4 | 0.71 |
Polycystic ovary syndrome | 1.6 | 1.4 | 0.14 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0.3 | 0.3 | |
primary biliary cholangitis | 0.4 | -0.4 | |
Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
Psoriasis | 1.1 | 0.4 | 1.75 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 1.3 | -0.08 |
Rosacea | 0.7 | 0.3 | 1.33 |
Schizophrenia | 1.8 | 0.9 | 1 |
scoliosis | 0.3 | -0.3 | |
Sjögren syndrome | 0.3 | 1 | -2.33 |
Sleep Apnea | 0.6 | 0.6 | 0 |
Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 0.6 | 0.7 | -0.17 |
Systemic Lupus Erythematosus | 1.1 | 0.9 | 0.22 |
Tic Disorder | 0.6 | 0.3 | 1 |
Tourette syndrome | 0.1 | 0.3 | -2 |
Type 1 Diabetes | 1.3 | 1 | 0.3 |
Type 2 Diabetes | 2.3 | 2.6 | -0.13 |
Ulcerative colitis | 1.1 | 2.9 | -1.64 |
Unhealthy Ageing | 0.8 | 0.6 | 0.33 |
Vitiligo | 1.4 | 0.4 | 2.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]